S. Munk

发表

Barbara H. Munk, Susan M. Miller, W. Moos, 2017 .

Backgrounder: Medicinal chemistry: Research, discovery, art, science

Barbara H. Munk, Susan M. Miller, W. Moos, 2017 .

Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit.

D. Boger, S. Munk, H. Zarrinmayeh, 1991, Proceedings of the National Academy of Sciences of the United States of America.

State‐of‐the‐art process for the safe synthesis of anticancer drugs

S. Munk, Vince Ammoscato, J. Henderson, 2010 .

Graduate and postgraduate education at a crossroads

Barbara H. Munk, Susan M. Miller, W. Moos, 2017 .

The big leap

Barbara H. Munk, Susan M. Miller, W. Moos, 2017 .

Drug discovery: Standing on the shoulders of giants

Walter H. Moos, Barbara H. Munk, Stephen A. Munk, 2017 .

Total synthesis and evaluation of (.+-.)-N-(tert-butoxycarbonyl)-CBI, (.+-.)-CBI-CDPI1, and (.+-.)-CBI-CDPI2: CC-1065 functional agents incorporating the equivalent 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI) left-hand subunit

D. Boger, R. Wysocki, S. Munk, 1989 .

DNA alkylation properties of enhanced functional analogs of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI) alkylation subunit

D. Boger, S. Munk, 1992 .

(+)-CC 1065 DNA alkylation : key studies demonstrating a noncovalent binding selectivity contribution to the alkylation selectivity

D. Boger, S. Munk, H. Zarrinmayeh, 1991 .

(+)-CC-1065 DNA alkylation : observation of an unexpected relationship between cyclopropane electrophile reactivity and the intensity of DNA alkylation

D. Boger, S. Munk, T. Ishizaki, 1991 .

Synthesis and preliminary evaluation of (+)-CBI-indole2: an enhanced functional analog of (+)-CC-1065

D. Boger, S. Sakya, S. Munk, 1991 .

An alternative and convenient strategy for generation of substantial quantities of singly 5'-32P-end-labeled double-stranded DNA for binding studies: development of a protocol for examination of functional features of (+)-CC-1065 and the duocarmycins that contribute to their sequence-selective DNA a

D. Boger, M. Bina, S. Munk, 1991, Tetrahedron.

Duocarmycin-pyrindamycin DNA alkylation properties and identification, synthesis, and evaluation of agents incorporating the pharmacophore of the duocarmycin-pyrindamycin alkylation subunit. Identification of the CC-1065 duocarmycin common pharmacophore

D. Boger, S. Munk, H. Zarrinmayeh, 1990 .

Synthesis and evaluation of aborted and extended CC-1065 functional analogs: (+)- and (-)-CPI-PDE-I1, (+)- and (-)-CPI-CDPI1, and (.+-.)-, (+)-, and (-)-CPI-CDPI3. Preparation of key partial structures and definition of an additional functional role of the CC-1065 central and right-hand subunits

R. S. Coleman, D. Boger, S. Sakya, 1990 .

Total Synthesis and Evaluation of (.+-.)-N-(tert.-Butyloxycarbonyl)-CBI, (.+-.)-CBI-CDPI1, and (.+-.)-CBI-CDPI2: CC-1065 Functional Agents Incorporating the Equivalent 1,2,9,9a-Tetrahydrocycloprop(1,2-c)benz(1,2-e)indol-4-one (CBI) Le

D. Boger, R. Wysocki, S. Munk, 1989 .

DNA Cleavage by 4-Alkynyl-3-methoxy-4-hydroxycyclobutenones

S. Munk, V. Coghlan, M. Reed, 1994 .

Analogs of UK 14,304: Structural features responsible for α2 adrenoceptor activity

L. Wheeler, S. Munk, M. Garst, 1995 .

Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin-Pyrindamycin Alkylation Subunit. Identification of the CC-1065-Duocarmycin Common Pharmacophore.

D. Boger, S. Munk, H. Zarrinmayeh, 1991 .

Synthesis and Evaluation of Aborted and Extended CC-1065 Functional Analogues: (+)- and (-)-CPI-PDE-I1, (+)- and (-)-CPI-CDPI1, and (.+-.)-, (+)-, and (-)-CPI-CDPI3. Preparation of Key Partial Structures and Definition of an Additiona

R. S. Coleman, D. Boger, S. Sakya, 1990 .

(+)-CC-1065 DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity.

D. Boger, S. Munk, H. Zarrinmayeh, 1991 .

Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation.

C. D. Thompson, T. Macdonald, S. Munk, 1997, Experimental eye research.

Drug discovery: Standing on the shoulders of giants

Walter H. Moos, Barbara H. Munk, Stephen A. Munk, 2017 .

Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.

R. Lai, D. Hasson, L. Wheeler, 1996, Journal of medicinal chemistry.

Synthesis and Pharmacologic Evaluation of 2‐endo‐Amino‐3‐exo‐ isopropylbicyclo(2.2.1)heptane: A Potent Imidazoline1 Receptor Specific Agent.

R. Lai, D. Hasson, L. Wheeler, 1996 .

Two-year certification and degree programs

Barbara H. Munk, Susan M. Miller, W. Moos, 2017 .

Research and discovery

Susan M. Miller, Walter H. Moos, Barbara H. Munk, 2017 .

Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase.

S. Munk, M. Garst, S. Vekich, 1996, Xenobiotica; the fate of foreign compounds in biological systems.

Backgrounder: Medicinal chemistry: Research, discovery, art, science

Barbara H. Munk, Susan M. Miller, W. Moos, 2017 .

Chemical development: Synthetic studies and engineering aspects

Walter H. Moos, Barbara H. Munk, Stephen A. Munk, 2017 .

The Role of the Chemical Development, Quality, and Regulatory Affairs Teams in Turning a Potent Agent into a Registered Product

S. A. Munk, S. Munk, 2007 .